Cyclacel Pharmaceuticals Inc.
13F holders, Q3 2024 (September 30)15holders −1
2new positions
3sold out
1famous investor
$0.99avg. 13F price*
At the end of Q3 2024, 15 institutions reported holding Cyclacel Pharmaceuticals Inc. in their 13F filings, down 1 from Q2 2024. 2 opened new positions and 3 sold out. The largest holders were Armistice Capital, LLC ($144K), Point72 Asset Management ($15K) and Acadian Asset Management LLC ($14K). One famous investor held it Steve Cohen (0.0% of Point72 Asset Management's portfolio).
- Company
- Cyclacel Pharmaceuticals Inc.
- CUSIP
- 23254L801
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $10K |
| Exits | 3 | $37K |
All 13F filers, Q2 2024 → Q3 2024: 22,102 shares bought and 49,044 shares sold, net −26,942 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Armistice Capital, LLC | 0.00% | Add +8.2% | 145,000 | $144K |
| Point72 Asset Management | 0.00% | No change | 15,333 | $15K |
| Acadian Asset Management LLC | 0.00% | No change | 14,285 | $14K |
| UBS Group AG | 0.00% | Reduce -67.0% | 12,553 | $12K |
| Geode Capital Management, LLC | 0.00% | New | 10,598 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +14.2% | 4,010 | $4K |
| McIlrath & Eck, LLC | 0.00% | Reduce -80.0% | 166 | $164 |
| Activest Wealth Management | 0.00% | No change | 133 | $132 |
| Osaic Holdings, Inc. | 0.00% | No change | 126 | $124 |
| Morgan Stanley | 0.00% | No change | 80 | $79 |
| Wells Fargo & Company | 0.00% | No change | 33 | $33 |
| Signaturefd, LLC | 0.00% | No change | 20 | $20 |
| Bank of America Corp. | 0.00% | Add +50.0% | 15 | $15 |
| Harbour Investments, Inc. | 0.00% | No change | 13 | $13 |
| Danske Bank A/S | 0.00% | New | 2 | $2 |
"% of holder's portfolio" is CYCLACEL PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Cyclacel Pharmaceuticals Inc. the manager owns.